Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology

Stefano Bianchi, Filippo Aucella, Luca De Nicola, Simonetta Genovesi, Ernesto Paoletti, Giuseppe Regolisti

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Hyperkalemia (HK) is the most common electrolyte disturbance observed in patients with kidney disease, particularly in those in whom diabetes and heart failure are present or are on treatment with renin–angiotensin–aldosterone system inhibitors (RAASIs). HK is recognised as a major risk of potentially life threatening cardiac arrhythmic complications. When an acute reduction of renal function manifests, both in patients with chronic kidney disease (CKD) and in those with previously normal renal function, HK is the main indication for the execution of urgent medical treatment and the recourse to extracorporeal replacement therapies. In patients with end-stage renal disease, the presence of HK not responsive to medical therapy is an indication at the beginning of chronic renal replacement therapy. HK can also be associated indirectly with the progression of CKD, because the finding of high potassium values leads to withdrawal of treatment with RAASIs, which constitute the first choice nephro-protective treatment. It is therefore essential to identify patients at risk of developing HK, and to implement therapeutic interventions aimed at preventing and treating this dangerous complication of kidney disease. Current strategies aimed at the prevention and treatment of HK are still unsatisfactory, as evidenced by the relatively high prevalence of HK also in patients under stable nephrology care, and even in the ideal setting of randomized clinical trials where optimal treatment and monitoring are mandatory. This position paper will review the main therapeutic interventions to be implemented for the prevention, detection and treatment of HK in patients with CKD on conservative care, in those on dialysis, in patients in whom renal disease is associated with diabetes, heart failure, resistant hypertension and who are on treatment with RAASIs, and finally in those presenting with severe acute HK.

Original languageEnglish
JournalJournal of Nephrology
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Hyperkalemia
Nephrology
Kidney Diseases
Therapeutics
Chronic Renal Insufficiency
Kidney
Heart Failure
Renal Replacement Therapy
Electrolytes
Chronic Kidney Failure
Dialysis
Potassium
Randomized Controlled Trials

Keywords

  • Acute kidney injury
  • Chronic kidney disease
  • Hyperkalemia
  • Renin–angiotensin–aldosterone inhibitors

ASJC Scopus subject areas

  • Nephrology

Cite this

Management of hyperkalemia in patients with kidney disease : a position paper endorsed by the Italian Society of Nephrology. / Bianchi, Stefano; Aucella, Filippo; De Nicola, Luca; Genovesi, Simonetta; Paoletti, Ernesto; Regolisti, Giuseppe.

In: Journal of Nephrology, 01.01.2019.

Research output: Contribution to journalReview article

@article{249948b576044655bdbb3e27d2bcec07,
title = "Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology",
abstract = "Hyperkalemia (HK) is the most common electrolyte disturbance observed in patients with kidney disease, particularly in those in whom diabetes and heart failure are present or are on treatment with renin–angiotensin–aldosterone system inhibitors (RAASIs). HK is recognised as a major risk of potentially life threatening cardiac arrhythmic complications. When an acute reduction of renal function manifests, both in patients with chronic kidney disease (CKD) and in those with previously normal renal function, HK is the main indication for the execution of urgent medical treatment and the recourse to extracorporeal replacement therapies. In patients with end-stage renal disease, the presence of HK not responsive to medical therapy is an indication at the beginning of chronic renal replacement therapy. HK can also be associated indirectly with the progression of CKD, because the finding of high potassium values leads to withdrawal of treatment with RAASIs, which constitute the first choice nephro-protective treatment. It is therefore essential to identify patients at risk of developing HK, and to implement therapeutic interventions aimed at preventing and treating this dangerous complication of kidney disease. Current strategies aimed at the prevention and treatment of HK are still unsatisfactory, as evidenced by the relatively high prevalence of HK also in patients under stable nephrology care, and even in the ideal setting of randomized clinical trials where optimal treatment and monitoring are mandatory. This position paper will review the main therapeutic interventions to be implemented for the prevention, detection and treatment of HK in patients with CKD on conservative care, in those on dialysis, in patients in whom renal disease is associated with diabetes, heart failure, resistant hypertension and who are on treatment with RAASIs, and finally in those presenting with severe acute HK.",
keywords = "Acute kidney injury, Chronic kidney disease, Hyperkalemia, Renin–angiotensin–aldosterone inhibitors",
author = "Stefano Bianchi and Filippo Aucella and {De Nicola}, Luca and Simonetta Genovesi and Ernesto Paoletti and Giuseppe Regolisti",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s40620-019-00617-y",
language = "English",
journal = "Journal of Nephrology",
issn = "1121-8428",
publisher = "Springer International Publishing",

}

TY - JOUR

T1 - Management of hyperkalemia in patients with kidney disease

T2 - a position paper endorsed by the Italian Society of Nephrology

AU - Bianchi, Stefano

AU - Aucella, Filippo

AU - De Nicola, Luca

AU - Genovesi, Simonetta

AU - Paoletti, Ernesto

AU - Regolisti, Giuseppe

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Hyperkalemia (HK) is the most common electrolyte disturbance observed in patients with kidney disease, particularly in those in whom diabetes and heart failure are present or are on treatment with renin–angiotensin–aldosterone system inhibitors (RAASIs). HK is recognised as a major risk of potentially life threatening cardiac arrhythmic complications. When an acute reduction of renal function manifests, both in patients with chronic kidney disease (CKD) and in those with previously normal renal function, HK is the main indication for the execution of urgent medical treatment and the recourse to extracorporeal replacement therapies. In patients with end-stage renal disease, the presence of HK not responsive to medical therapy is an indication at the beginning of chronic renal replacement therapy. HK can also be associated indirectly with the progression of CKD, because the finding of high potassium values leads to withdrawal of treatment with RAASIs, which constitute the first choice nephro-protective treatment. It is therefore essential to identify patients at risk of developing HK, and to implement therapeutic interventions aimed at preventing and treating this dangerous complication of kidney disease. Current strategies aimed at the prevention and treatment of HK are still unsatisfactory, as evidenced by the relatively high prevalence of HK also in patients under stable nephrology care, and even in the ideal setting of randomized clinical trials where optimal treatment and monitoring are mandatory. This position paper will review the main therapeutic interventions to be implemented for the prevention, detection and treatment of HK in patients with CKD on conservative care, in those on dialysis, in patients in whom renal disease is associated with diabetes, heart failure, resistant hypertension and who are on treatment with RAASIs, and finally in those presenting with severe acute HK.

AB - Hyperkalemia (HK) is the most common electrolyte disturbance observed in patients with kidney disease, particularly in those in whom diabetes and heart failure are present or are on treatment with renin–angiotensin–aldosterone system inhibitors (RAASIs). HK is recognised as a major risk of potentially life threatening cardiac arrhythmic complications. When an acute reduction of renal function manifests, both in patients with chronic kidney disease (CKD) and in those with previously normal renal function, HK is the main indication for the execution of urgent medical treatment and the recourse to extracorporeal replacement therapies. In patients with end-stage renal disease, the presence of HK not responsive to medical therapy is an indication at the beginning of chronic renal replacement therapy. HK can also be associated indirectly with the progression of CKD, because the finding of high potassium values leads to withdrawal of treatment with RAASIs, which constitute the first choice nephro-protective treatment. It is therefore essential to identify patients at risk of developing HK, and to implement therapeutic interventions aimed at preventing and treating this dangerous complication of kidney disease. Current strategies aimed at the prevention and treatment of HK are still unsatisfactory, as evidenced by the relatively high prevalence of HK also in patients under stable nephrology care, and even in the ideal setting of randomized clinical trials where optimal treatment and monitoring are mandatory. This position paper will review the main therapeutic interventions to be implemented for the prevention, detection and treatment of HK in patients with CKD on conservative care, in those on dialysis, in patients in whom renal disease is associated with diabetes, heart failure, resistant hypertension and who are on treatment with RAASIs, and finally in those presenting with severe acute HK.

KW - Acute kidney injury

KW - Chronic kidney disease

KW - Hyperkalemia

KW - Renin–angiotensin–aldosterone inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85066906653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066906653&partnerID=8YFLogxK

U2 - 10.1007/s40620-019-00617-y

DO - 10.1007/s40620-019-00617-y

M3 - Review article

C2 - 31119681

AN - SCOPUS:85066906653

JO - Journal of Nephrology

JF - Journal of Nephrology

SN - 1121-8428

ER -